• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.

    5/8/26 9:22:52 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCAX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    BICARA THERAPEUTICS INC.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)




    055477103

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    055477103


    1Names of Reporting Persons

    Red Tree GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,170,509.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,170,509.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,170,509.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    055477103


    1Names of Reporting Persons

    Red Tree Venture Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,170,509.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,170,509.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,170,509.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    055477103


    1Names of Reporting Persons

    Heath Lukatch
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,170,509.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,170,509.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,170,509.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BICARA THERAPEUTICS INC.
    (b)Address of issuer's principal executive offices:

    116 Huntington Avenue, Suite 703, Boston, MA, 02116.
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") are: Red Tree GP, LLC (Red Tree GP I") Red Tree Venture Fund, L.P. ("Red Tree Fud I") Heath Lukatch, PhD ("Lukatch") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G/A.
    (b)Address or principal business office or, if none, residence:

    2055 Woodside Road, Suite 270 Redwood City, CA 94061
    (c)Citizenship:

    Red Tree GP I Delaware Red Tree Fund I Delaware Lukatch United States
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    055477103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of 3,170,509 shares of common stock held directly by Red Tree Fund I. Red Tree GP I is the general partner of Red Tree Fund I and Lukatch is the managing director of Red Tree GP I. Each of Red Tree GP I and Lukatch possesses power to direct the voting and disposition of the securities held by Red Tree Fund I.
    (b)Percent of class:

    Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 65,467,187 shares of the Issuer's common stock outstanding as of March 24, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 30, 2026.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Red Tree GP, LLC
     
    Signature:/s/ Heath Lukatch, PhD
    Name/Title:By Heath Lukatch, PhD, Managing Director
    Date:05/08/2026
     
    Red Tree Venture Fund, L.P.
     
    Signature:/s/ Heath Lukatch, PhD
    Name/Title:By Red Tree GP, LLC, its General Partner, By Heath Lukatch, PhD, Managing Director
    Date:05/08/2026
     
    Heath Lukatch
     
    Signature:/s/ Heath Lukatch, PhD
    Name/Title:Heath Lukatch, PhD
    Date:05/08/2026
    Exhibit Information

    Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Reporting Persons' Schedule 13G filed with the SEC on September 26, 2024).

    Get the next $BCAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCAX

    DatePrice TargetRatingAnalyst
    5/11/2026$42.00Buy
    Guggenheim
    3/25/2026$35.00Buy
    BofA Securities
    1/29/2026$31.00Mkt Perform
    Citizens JMP
    1/8/2026$28.00Buy
    BTIG Research
    12/18/2025$18.00Neutral
    Mizuho
    8/19/2025$36.00Overweight
    Piper Sandler
    5/23/2025$8.00Underweight → Equal Weight
    Wells Fargo
    4/17/2025$8.00Underweight
    Wells Fargo
    More analyst ratings

    $BCAX
    SEC Filings

    View All

    SEC Form 144 filed by Bicara Therapeutics Inc.

    144 - Bicara Therapeutics Inc. (0002023658) (Subject)

    6/1/26 4:02:59 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicara Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Bicara Therapeutics Inc. (0002023658) (Filer)

    5/21/26 5:04:36 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.

    SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)

    5/15/26 5:06:19 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Hyep Ivan exercised 9,200 shares at a strike of $3.79 and sold $187,883 worth of shares (9,200 units at $20.42) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

    5/26/26 5:48:13 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Mazumdar Claire exercised 15,000 shares at a strike of $3.79 and sold $300,579 worth of shares (15,000 units at $20.04) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

    5/20/26 4:07:47 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and COO Cohlhepp Ryan exercised 8,000 shares at a strike of $3.79 and sold $253,649 worth of shares (12,500 units at $20.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 191,641 units (SEC Form 4)

    4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

    5/18/26 4:24:16 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $4,800,000 worth of shares (300,000 units at $16.00) (SEC Form 4)

    4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

    3/2/26 4:22:58 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Possible Members of 10% Group Flynn James E converted options into 1,725,174 shares and bought $1,260,000 worth of shares (70,000 units at $18.00) (SEC Form 4)

    4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

    9/17/24 6:16:55 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

       At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely to remain progression-free and alive Company to h

    5/21/26 5:00:00 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara's 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara's Chief Commercial Officer. Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $22.58 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on

    5/13/26 8:30:00 AM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

    Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up data from Phase 1b study of ficerafusp alfa in combination with pembrolizumab in 1L R/M HPV-negative HNSCC patients to be presented at ASCO 2026 Bill Schelman, M.D., Ph.D., EVP, Clinical Development promoted to Chief Medical Officer, and David Raben, M.D., Chief Medical Officer transitioned to serve as a Senior Executive Advisor to the company Chris Sarchi appointed as Chief Commercial Officer BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX) today announce

    5/11/26 7:30:00 AM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Bicara Therapeutics with a new price target

    Guggenheim initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $42.00

    5/11/26 8:29:02 AM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Bicara Therapeutics with a new price target

    BofA Securities initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $35.00

    3/25/26 8:29:02 AM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Bicara Therapeutics with a new price target

    Citizens JMP initiated coverage of Bicara Therapeutics with a rating of Mkt Perform and set a new price target of $31.00

    1/29/26 7:01:51 AM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCAX
    Financials

    Live finance-specific insights

    View All

    Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

       At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely to remain progression-free and alive Company to h

    5/21/26 5:00:00 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET

    BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast,

    5/4/26 8:30:00 AM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET

    BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To acces

    3/23/26 8:30:00 AM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCAX
    Leadership Updates

    Live Leadership Updates

    View All

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

    CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

    6/11/25 4:05:00 PM ET
    $BCAX
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BCAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bicara Therapeutics Inc.

    SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

    9/26/24 4:30:56 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Bicara Therapeutics Inc.

    SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

    9/26/24 4:16:04 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Bicara Therapeutics Inc.

    SC 13D - Bicara Therapeutics Inc. (0002023658) (Subject)

    9/23/24 4:17:42 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care